NCT04599634 2025-02-04Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesNational Institutes of Health Clinical Center (CC)Phase 1 Completed11 enrolled 16 charts